We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05559541
Recruitment Status : Not yet recruiting
First Posted : September 29, 2022
Last Update Posted : September 29, 2022
Sponsor:
Information provided by (Responsible Party):
Akeso

Brief Summary:
This is a Phase Ib/II Study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK119 combined with AK104 in tumor patients.

Condition or disease Intervention/treatment Phase
Solid Tumor, Adult Drug: AK119 Drug: AK104 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 102 participants
Allocation: N/A
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-Label, Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of AK119 Combined With AK104 in Patients With Advanced Solid Tumors
Estimated Study Start Date : November 2022
Estimated Primary Completion Date : March 2024
Estimated Study Completion Date : September 2024

Arm Intervention/treatment
Experimental: AK119+AK104
AK119 and AK104 IV every 2 or every 3 weeks.
Drug: AK119
AK119 is an anti-CD73 monoclonal antibody.

Drug: AK104
AK104 is an anti-PD-1 and CTLA-4 bispecific antibody.




Primary Outcome Measures :
  1. Number of subjects with dose limiting toxicities (DLTs) [ Time Frame: During the first 3 or 4 weeks ]
    DLTs will be assessed during the first 3 or 4 weeks of treatment. DLTs are defined as toxicities that meet pre-defined severity criteria, and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the DLT observation period.

  2. Number of subjects with adverse events (AEs) [ Time Frame: From the time of informed consent signed through 90 days after the last dose of study drug. ]
    AE refers to any untoward medical occurrence or deterioration of existing medical event after the subject signed the ICF, whether or not considered related to the study treatment.

  3. Objective response rate (ORR) [ Time Frame: Up to 2 years ]
    ORR is defined as the proportion of subjects with CR or PR (based on RECIST Version 1.1).


Secondary Outcome Measures :
  1. Progression-free survival (PFS) [ Time Frame: Up to 2 years ]
    PFS is defined as the time from the start of treatment until the first documentation of disease progression or death due to any cause, whichever occurs first (based on RECIST Version 1.1).

  2. Disease control rate (DCR) [ Time Frame: Up to 2 years ]
    DCR is defined as the proportion of subjects with CR, PR, or SD (based on RECIST Version 1.1).

  3. Duration of response (DoR) [ Time Frame: Up to 2 years ]
    Duration of response is defined as the duration from the first documentation of objective response to the first documented disease progression (based on RECIST Version 1.1) or death due to any cause, whichever occurs first.

  4. Time to response (TTR) [ Time Frame: Up to 2 years ]
    Time to response (TTR) is defined as the time from the start of the treatment to the first objective tumor response observed for patients who achieved CR or PR (based on RECIST Version 1.1).

  5. Overall survival (OS) [ Time Frame: Up to 2 years ]
    OS defined as the time from the first dose to death from any cause.

  6. PK parameters [ Time Frame: From first dose of study drug through last dose ]
    The PK parameters include serum concentrations of AK119 and AK104 at different timepoints after study drug administration.

  7. Immunogenicity assessment [ Time Frame: From first dose of study drug through 30 days after last dose ]
    The immunogenicity of AK119 and AK104 will be assessed by summarizing the number of subjects who develop detectable antidrug antibodies (ADAs).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects must sign the written informed consent form (ICF) voluntarily.
  2. Age ≥ 18 years.
  3. Eastern Cooperative Oncology Group (ECOG) Performance Status: 0 to1.
  4. Life expectancy ≥12 weeks.
  5. Subjects must have histologically or cytologically confirmed advanced solid tumor that is refractory or relapsed to the current standard therapies, or for which no effective standard therapy is available.
  6. Subjects must have evaluable lesions according to RECIST v1.1.
  7. Subjects must have adequate organ function.
  8. Female subjects of childbearing potential and male subjects with female partners of childbearing potential must agree to use effective barrier methods of contraception during the study and for 120 days after last dose of study drug.

Exclusion Criteria:

  1. Prior malignancy active within the previous 3 years except for the locally curable cancers that have been apparently cured.
  2. Being involved in another clinical study, except for observational clinical studies or follow-up period of interventional studies.
  3. Have exposured to other products targeting T cell costimulation or immunocheckpoint pathway excepts for PD-1/PD-L1 inhibitor.
  4. Anticancer therapy (e.g., chemotherapy, radiotherapy, etc.) within 4 weeks prior to the first dose of investigational product; Anticancer small-molecule targeted agent (e.g., tyrosine kinase inhibitor) within 2 weeks prior to the first dose of investigational product.
  5. Subjects with spinal cord compression or active brain metastases, except for subjects with untreated and asymptomatic brain metastases or with stable brain metastases after treatment.
  6. Subjects with pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
  7. Subjects whose imaging shows that the tumor has invaded important blood vessels or the investigator judges that the tumor is very likely to invade important blood vessels and cause fatal bleeding during the study.
  8. Toxicities of prior anticancer therapy have not resolved to ≤ Grade 1 (NCI-CTCAE version 5.0).
  9. Patients with clinically significant cardio-cerebrovascular or venous thromboembolic disease.
  10. Active autoimmune diseases or history of autoimmune diseases that may relapse.
  11. History of interstitial lung disease or noninfectious pneumonitis.
  12. Major surgery or trauma within 4 weeks prior to first dose of investigational product. Unhealed wound, ulcer or fracture within 4 weeks prior to first dose of investigational product.
  13. Any condition that required systemic treatment with corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive agents within 14 days prior to the first dose of investigational product.
  14. Receipt of live attenuated vaccines within 4 weeks prior to the first dose of investigational product.
  15. Previous history of severe hypersensitivity reactions to other monoclonal antibodies.
  16. Patients are pregnant or breastfeeding, or plan to breastfeed during the study.
  17. Previous organ transplantation or allogeneic hematopoietic stem cell transplantation.
  18. Any other conditions that, in the opinion of the Investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05559541


Contacts
Layout table for location contacts
Contact: Ting Liu, MD +86(0760)8987 3999 clinicaltrials@akesobio.com

Sponsors and Collaborators
Akeso
Investigators
Layout table for investigator information
Principal Investigator: Jihui Hao, PhD Tianjin Medical University Cancer Insitute & Hospital
Layout table for additonal information
Responsible Party: Akeso
ClinicalTrials.gov Identifier: NCT05559541    
Other Study ID Numbers: AK119-104
First Posted: September 29, 2022    Key Record Dates
Last Update Posted: September 29, 2022
Last Verified: September 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms